Indivior Plc

Indivior Plc

INDV

Get informed when a big investor buys or sells

+ Follow
Market Cap$4.47B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Indivior PlcIndivior Plc12.6--175%3.2-0.4
$47.33

Target Price by Analysts

45.9% upsideIndivior Plc Target Price DetailsTarget Price
$-1.25

Current Fair Value

103.9% downside

Overvalued by 103.9% based on the discounted cash flow analysis.

Share Statistics

Market cap$4.47 Billion
Enterprise Value$4.36 Billion
Dividend Yield$- (-)
Earnings per Share$1.68
Beta1.11
Outstanding Shares125,352,000

Return

Return on Equity-175.00%ROE
Return on Assets21.05%
Return on Invested Capital81.10%

Valuation & Multiples

P/E Ratio12.62P/E Ratio
PEG14.12PEG
Price to Sales3.25Price to Sales
Price to Book Ratio-16.23Price to Book Ratio
Enterprise Value to Revenue3.38
Enterprise Value to EBIT12.86
Enterprise Value to Net Income17
Total Debt to Enterprise0.01
Debt to Equity-0.44Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
August 4, 2026
EPS Estimate
$0.89
Average shareholder expectation
Revenue Estimate
$307.55 M
Average shareholder expectation

Next Earnings Call

Expected Date
October 29, 2026
EPS Estimate
$1.06
Average shareholder expectation
Revenue Estimate
$329.35 M
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio0.0000▼ 36.84%
Total Calls-▼ 100.00%
Total Puts-▼ 100.00%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %2.98%▼ 94.85%
Total Invested$133.88M▼ 97.34%
Investors Holding9▼ 339.00%

ESG Score

No data

About Indivior Plc

CEO: Shaun Thaxter

Indivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, Subutex Tablet, ...